FRANKFURT, March 17 (Reuters) - Germany's Merck KGaA on Tuesday placed a $4 billion bond with institutional investors to help fund its $17 billion acquisition of U.S. lab supplies company Sigma - Aldrich .
a decade of consistent price increases, we estimate that Rebif's margin is well above the company average. The Sigma - Aldrich deal is still expected to close in mid-2015. The transaction will help reduce Merck's reliance on its underperforming
Sigma - Aldrich 's fourth-quarter results slightly exceeded our expectations thanks to particularly strong growth in the commercial business
Sigma - Aldrich ’s third-quarter results mostly matched our expectations, with strength in the applied segment offsetting ongoing sluggish performance
Sept 23 (Reuters) - The large premium Germany's Merck KGaA agreed to pay in a $17 billion acquisition of Sigma - Aldrich Corp shines a spotlight on, and potentially raises the value of, a company Merck...
Merck KGaA intends to expand the company’s life sciences operations with a $17 billion all-cash acquisition of Sigma - Aldrich , which comes to approximately $140 per share. The deal will continue to diversify Merck’s operations, while also
Ongoing research budget spending pressure and the delay of large contract manufacturing orders sustained weak growth for Sigma - Aldrich during the second quarter. Gross margin expansion and tight operating cost controls kept earnings growth on track
We don’t plan to change our $87 fair value estimate or narrow moat rating for Sigma - Aldrich after the company’s first-quarter results mostly met our expectations. Organic revenue growth of 3% fell slightly below our
We don't expect to make any changes to our fair value estimate for Sigma - Aldrich as the company’s performance continues to mostly track our expectations. Consistent with our forecast, organic revenue increased
Sigma - Aldrich reported third-quarter results in line with our expectations. Management increased the lower end of its EPS outlook on a favorable